Annuncio pubblicitario
Italia markets close in 2 hours 32 minutes
  • FTSE MIB

    34.151,19
    -508,36 (-1,47%)
     
  • Dow Jones

    38.852,86
    -216,74 (-0,55%)
     
  • Nasdaq

    17.019,88
    +99,08 (+0,59%)
     
  • Nikkei 225

    38.556,87
    -298,50 (-0,77%)
     
  • Petrolio

    80,34
    +0,51 (+0,64%)
     
  • Bitcoin EUR

    62.557,11
    -365,20 (-0,58%)
     
  • CMC Crypto 200

    1.458,53
    -26,17 (-1,76%)
     
  • Oro

    2.341,80
    -14,70 (-0,62%)
     
  • EUR/USD

    1,0851
    -0,0009 (-0,09%)
     
  • S&P 500

    5.306,04
    +1,32 (+0,02%)
     
  • HANG SENG

    18.477,01
    -344,15 (-1,83%)
     
  • Euro Stoxx 50

    4.965,48
    -64,87 (-1,29%)
     
  • EUR/GBP

    0,8512
    +0,0011 (+0,14%)
     
  • EUR/CHF

    0,9889
    -0,0026 (-0,26%)
     
  • EUR/CAD

    1,4838
    +0,0037 (+0,25%)
     

Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued an “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock

Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc.

PALO ALTO, Calif., Jan. 29, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX) announced that its majority stockholder, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted a “Frequently Asked Questions” document under the “Investors” section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento.

The FAQs address questions regarding the details of the dividend, including the record date, payment date, dividend ratio, distribution of the shares of Scilex common stock, how Sorrento stockholders can obtain certain information regarding the dividend, CUSIP information for Scilex common stock, and transfer restrictions on the dividend stock as well as questions related to issues that may arise with respect to the dividend in connection with short positions in Sorrento common stock.

The FAQs and related annexes are included in this press release and can also be found on Scilex’s website https://www.scilexholding.com/investors/faqs/

ANNUNCIO PUBBLICITARIO

FREQUENTLY ASKED QUESTIONS
REGARDING THE DIVIDEND OF SCILEX HOLDING COMPANY COMMON STOCK BY SORRENTO THERAPEUTICS, INC.

Q:

What is the dividend of Scilex Common Stock?

A:

On December 30, 2022, Sorrento Therapeutics, Inc. (Sorrento) announced that its board of directors declared a stock dividend (Dividend) consisting of an aggregate of 76,000,000 shares (Dividend Stock) of common stock of Scilex Holding Company held by Sorrento to record holders of:

  • Sorrento’s common stock (Record Common Holders) as of the close of business on the Record Date, and

  • certain warrants to purchase Sorrento common stock (which have or may have the right to participate in the Dividend pursuant to the terms of their respective warrants) (Record Warrant Holders and together with the Record Common Holders, Record Holders).


The Dividend would be apportioned on a pro rata basis among such holders in accordance with each holder’s ownership percentage of Sorrento common stock (assuming the full exercise of all outstanding warrants to purchase Sorrento common stock) as of the Record Date as set forth in the records of Sorrento’s transfer agent (with respect to the Record Common Holders) and Sorrento (with respect to the Record Warrant Holders) as of such date.

No fractional shares will be issued in connection with the Dividend and the Record Holders who otherwise would be entitled to receive fractional shares of Scilex common stock are entitled to receive cash (without interest or deduction) in lieu of such fractional shares in an amount equal to the product obtained by multiplying (a) $5.87 (which represents the closing price of Scilex common stock on the Record Date), by (b) the fraction of one share of Scilex common stock that such Record Holder would have otherwise been entitled to receive as a Dividend in respect of shares of Sorrento common stock held by such Record Holder (after aggregating all such fractional shares otherwise issuable to such Record Holder in connection with the Dividend) (Cash-in-Lieu Payment).

Q:

What was the Record Date for the Dividend?

A:

The Record Date for determining the Sorrento stockholders who are entitled to receive Dividend Stock was January 9, 2023.

Q:

What was the Payment Date for the Dividend Stock?

A:

The payment date for the Dividend Stock was January 19, 2023 (Payment Date).

Q:

What was the Dividend Ratio?

A:

The dividend ratio is 0.1410127 of a share of Scilex common stock for each one share of Sorrento common stock held (or underlying the applicable warrants) by the Record Holders as of the close of business on the Record Date.

Q:

Will I receive Dividend Stock?

A:

If you are a Record Common Holder, meaning you held Sorrento common stock as of the close of business on the Record Date, you are entitled to receive the Dividend Stock.

Q:

How do I know if I am a Record Common Holder?

A:

Stockholder of Record: Shares Registered in Your Name

If at the close of business on January 9, 2023, your shares of Sorrento common stock were registered directly in your name with Sorrento’s transfer agent, Pacific Stock Transfer Company (PST), then you are the stockholder of record for these shares and a Record Common Holder.

Beneficial Owner: Shares Registered in the Name of a Broker, Bank or Other Agent

If at the close of business on January 9, 2023, your shares of Sorrento common stock were held, not in your name, but rather in an account at a brokerage firm, bank, dealer or other similar organization, then you are the beneficial owner of shares held in “street name” and the organization holding your account is considered the stockholder of record, or the Record Common Holder, for purposes of the Dividend. As a beneficial owner, you have the right to direct your broker, bank or other agent with respect to the portion of Dividend Stock of which you are a beneficial owner and how it is reflected in your account.

Q:

What information and documentation was distributed to the Record Common Holders in connection with the Dividend?

A:

Stockholder of Record: Shares Registered in Your Name

If at the close of business on January 9, 2023, your shares of Sorrento common stock were registered directly in your name with Sorrento’s transfer agent, PST, then PST mailed the Information Statement to your address on record with PST. A copy of the Information Statement is attached to this FAQ as Annex A.

In addition, on January 19, 2023, Scilex’s transfer agent, Continental Stock Transfer & Trust Company (CST), distributed to you as a Record Common Holder (i) your pro rata portion of the Dividend Stock based on the Dividend Ratio and (ii) a Cash-in-Lieu Payment, if you otherwise were entitled to receive fractional shares of Scilex common stock.

The Dividend Stock is evidenced by a book-entry/DRS transaction confirmation (Dividend Confirmation), which Dividend Confirmation was mailed to your address on record with Sorrento’s transfer agent, PST. Accordingly, you are now a stockholder of record for your Dividend Stock and your shares are registered directly in your name with Scilex’s transfer agent, CST. If you were entitled to a Cash-in-Lieu Payment, a check for such payment was also mailed to your address on record with PST.

Beneficial Owner: Shares Registered in the Name of a Broker, Bank or Other Agent

If at the close of business on January 9, 2023, your shares of Sorrento common stock were held, not in your name, but rather in an account at a brokerage firm, bank, dealer or other similar organization, then you are the beneficial owner of shares held in “street name” and the organization holding your account is considered the stockholder of record, or the Record Common Holder, for purposes of the Dividend.

As a Record Common Holder, your broker or other agent should have received the Information Statement directly from PST. A copy of the Information Statement is attached to this FAQ as Annex A.

As a beneficial owner, you have the right to direct your broker, bank or other agent with respect to the Dividend Stock and how it is reflected in your account. Your broker can also assist you with obtaining your Cash-in-Lieu Payment, if any.

Q:

What if I did not receive the Information Statement or a Dividend Confirmation?

A:

A copy of the Information Statement is attached to this FAQ as Annex A.

Stockholder of Record: Shares Registered in Your Name

To obtain a copy of your Dividend Confirmation or to check on the status of your Cash-in-Lieu Payment (if any), please contact Scilex’s transfer agent, CST, by phone or email at:

Continental Stock Transfer & Trust Company
Telephone Number: 800-509-5586
Email Address: cstmail@continentalstock.com

Beneficial Owner: Shares Registered in the Name of a Broker, Bank or Other Agent

If you hold your shares in “street name” through a brokerage firm, bank, dealer or other similar organization, that organization received a Dividend Confirmation with respect to all Dividend Stock held by its customers and your pro rata portion of the Dividend Stock should be reflected in the statements you receive from your brokerage firm, bank, dealer or other similar organization.

A list of brokerage firms, banks, dealers and other similar organizations that received a Dividend Confirmation for shares held in “street name” is set forth on Annex B of this FAQ.

IF YOU HAVE ANY QUESTIONS REGARDING YOUR STATEMENT OR ANY OTHER COMMUNICATIONS FROM YOUR BROKER OR OTHER AGENT REGARDING THE DIVIDEND STOCK, PLEASE CONTACT THEM IMMEDIATELY.

Q:

Why does my brokerage statement indicate that the Dividend Stock has no value?

A:

If your brokerage statement indicates that the Dividend Stock has no value, please contact your brokerage firm, bank, dealer or other similar organization directly on an immediate basis to ensure that your brokerage statement is accurate and reflects the value of the Dividend Stock.

A list of brokerage firms, banks, dealers and other similar organizations that received a Dividend Confirmation for shares held in “street name” is set forth on Annex B of this FAQ.

Q:

What is the value of the Dividend Stock?

A:

Scilex common stock is listed on The Nasdaq Stock Market LLC under the symbol “SCLX”. You may obtain the trading and closing prices of Scilex common stock on Nasdaq’s website at Nasdaq.com.

Q:

What is the CUSIP number for shares of Scilex common stock?

A:

Scilex’s CUSIP number 80880W106.

Q:

Is there a separate CUSIP number for the Dividend Stock?

A:

No. The CUSIP number for the Dividend Stock is the same as all other shares of Scilex common stock.

Q:

My brokerage statement references an ISIN. What is an ISIN?

A:

ISIN stands for International Securities Identification Numbering system and is the global ISO standard for unique identification of financial and referential instruments, including equity, debt, derivatives and indices.

Note that the ISIN is not the CUSIP number. You should contact your broker immediately for more information about the ISIN and to have the broker include Scilex’s CUSIP number on your brokerage statement.

Q:

Can I transfer, sell, pledge, loan or otherwise dispose and transfer the Dividend Stock?

A:

No. The Dividend Stock you will receive on the Payment Date is subject to restrictions on transfer until May 11, 2023 and your shares of Dividend Stock will reflect the following restrictive legend, which restriction is also included in your Dividend Confirmation:

THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE TRANSFERRED, PLEDGED, HYPOTHECATED, LOANED, ENCUMBERED OR OTHERWISE DISPOSED OF WITHOUT THE CONSENT OF SCILEX HOLDING COMPANY (THE “COMPANY”) PRIOR TO MAY 11, 2023. A TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE SHALL BE DEEMED TO INCLUDE, WITHOUT LIMITATION, THE (A)  SALE OR ASSIGNMENT OF, OFFER TO SELL, CONTRACT OR AGREEMENT TO SELL, GRANT OF ANY OPTION TO PURCHASE OR OTHERWISE DISPOSE OF OR AGREEMENT TO DISPOSE OF, DIRECTLY OR INDIRECTLY, OR ESTABLISHMENT OR INCREASE OF A PUT EQUIVALENT POSITION OR LIQUIDATION WITH RESPECT TO OR DECREASE OF A CALL EQUIVALENT POSITION WITHIN THE MEANING OF SECTION 16 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (THE “EXCHANGE ACT”), WITH RESPECT TO, ANY SECURITY OF THE COMPANY, (B)  ENTRY INTO ANY SWAP OR OTHER ARRANGEMENT THAT TRANSFERS TO ANOTHER, IN WHOLE OR IN PART, ANY OF THE ECONOMIC CONSEQUENCES OF OWNERSHIP OF ANY SECURITY OF THE COMPANY, WHETHER ANY SUCH TRANSACTION IS TO BE SETTLED BY DELIVERY OF SUCH SECURITIES, IN CASH OR OTHERWISE, AND (C) ENGAGEMENT, WHETHER DIRECTLY OR INDIRECTLY, IN ANY (I) “SHORT SALE” (AS SUCH TERM IS DEFINED IN RULE 200 OF REGULATION SHO OF THE EXCHANGE ACT) OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE OR (II) HEDGING TRANSACTION, WHICH ESTABLISHES A NET SHORT POSITION WITH RESPECT TO ANY SECURITIES OF THE COMPANY (INCLUDING THE COMMON STOCK OF THE COMPANY), WITH RESPECT TO EACH OF CLAUSES (I) AND (II) HEREOF, EITHER FOR THE HOLDER’S OWN PRINCIPAL ACCOUNT OR FOR THE PRINCIPAL ACCOUNT OF ANY OTHER PERSON.

Q:

When will I be able to transfer, sell, pledge, or otherwise dispose and transfer the Dividend Stock?

A:

The foregoing transfer restrictions on the Dividend Stock will be removed on May 12, 2023, without any action required by you.

Q:

If I loaned my shares of Sorrento common stock to short sellers or any other party as of the Record Date, am I still entitled to receive Dividend Stock as of the Payment Date?

A:

Only Record Holders as of the Record Date are entitled to receive the Dividend Stock. If you were the Record Holder as of the Record Date and are entitled to receive the Dividend Stock, but have not received the Dividend Stock, you may be entitled to receive Dividend Stock from the short seller or other party who borrowed your shares of Sorrento common stock, whether through the lending programs implemented by your brokerage firm, bank, dealer and other similar organization or otherwise. If you were a Record Holder as of the Record Date and have not received your Dividend Stock, please consult with your financial advisor, broker or other agent immediately to determine how to receive your Dividend Stock.

Q:

What if my shares of Sorrento common stock were sold “short” as of the Record Date?

A:

According to Sorrento’s estimates, approximately 60 million or more shares of Sorrento common stock were sold “short” as of the Record Date.   In the event your shares of Sorrento common stock were held through a brokerage firm, bank, dealer or other similar organization and were sold “short” as of the Record Date, you should consult with your financial advisor, broker or other agent immediately to determine whether you may also be deemed “short” Scilex common stock as a result of the Dividend, as well as any obligations required for you to cover your “short” position(s).

Note that “naked short” sales or “naked short” positions in any Sorrento common stock may constitute a violation of SEC Regulation SHO.

Q:

What if my shares of Scilex common stock issued as the Dividend Stock were sold “short” because my Sorrento common stock was sold “short” as of the Payment Date?

A:

According to Sorrento’s estimates, approximately 8.4 million or more shares of Scilex common stock were deemed to have been sold “short” as of the Payment Date as a result of the “short” positions of the underlying Sorrento common stock referenced above.

In the event your shares of Scilex common stock issued as the Dividend Stock are held through a brokerage firm, bank, dealer or other similar organization and were deemed to have been sold “short” as of the Payment Date as a result of a “short” position in Sorrento’s underlying common stock referenced above, you should consult with your financial advisor, broker or other agent immediately to determine any obligations required to cover your “short” position(s) of Scilex common shares.

Note that “naked short” sales or “naked short” positions in any Scilex common stock may constitute a violation of SEC Regulation SHO.

Q:

If I am deemed “short” the Scilex Divided Stock, what is the borrowing cost for my “short” position in shares of Scilex common stock?

A:

According to recent reports from various brokerage firms lending shares of Scilex common stock for “short” sales, the current borrowing interest rate is estimated to be over 400% per year. If your Scilex common stock is held through a brokerage firm, bank, dealer or other similar organization and you have a “short” position, please consult with your financial advisor, broker or other agent immediately to determine your borrowing interest rate for your “short” position(s) of Scilex common stock.

Note that “naked short” sales or “naked short” positions in any Scilex common stock may constitute a violation of SEC Regulation SHO.

Q:

What is the estimated “short” position of the Scilex common stock as of the Payment Date?

A:

According to Sorrento’s estimates, approximately 8.4 million or more shares of Scilex common stock were deemed to have been sold “short” as of the Payment Date.

If your Scilex common stock is held through a brokerage firm, bank, dealer or other similar organization and your shares of Scilex common stock were sold “short” as of the Payment Date, you should consult with your financial advisor, broker or other agent immediately to determine any obligations required to cover your “short” position(s) of Scilex common shares.

Note that “naked short” sales or “naked short” positions in any Scilex common stock may constitute a violation of SEC Regulation SHO.

Q:

What is the public float (i.e., unrestricted and freely tradeable shares) of the Scilex common stock as of the Payment Date?

A:

Approximately 2.5 million shares of Scilex common stock were unrestricted and freely tradable as of the Payment Date.   This public float may be increased if some or all of the unrestricted and freely tradable “public” warrants to purchase shares of Scilex common stock are exercised. The exercise price of the Scilex “public” warrants is $11.50 per share (subject to adjustment for recapitalizations, stock splits and similar transactions and as provided in the warrants).

Q:

How many Scilex warrants are currently outstanding?

A:

There are approximately 11 million unrestricted and freely tradable warrants to purchase shares of Scilex common stock outstanding and such warrants have an exercise price of $11.50 per share (subject to adjustment for recapitalizations, stock splits and similar transactions and as provided in the warrants). Sorrento owns approximately 4.5 million Scilex warrants (of which approximately 3.1 million are private warrants) and Vickers Venture Fund VI Pte Ltd and its affiliates own one million Scilex private warrants.

Q:

Will Scilex management take any actions with respect to the substantial “naked short” positions of Scilex common stock that represents approximately three times the public float of Scilex common stock?

A:

Yes. The management teams of both Scilex and Sorrento are in consultation with their outside legal counsel to explore all legal avenues to resolve the imbalance of the substantial “naked short” positions of Scilex common stock estimated to be approximately 8.4 million or more shares of Scilex common stock as compared to the limited public float of approximately 2.5 million shares of Scilex common stock.

Scilex and Sorrento will send a written notification to the Financial Industry Regulatory Authority (FINRA), which oversees U.S. broker-dealers, to advise FINRA of the substantial “naked short” positions of Scilex common stock. Sorrento and Scilex will offer to work closely with FINRA and other regulatory agencies to enforce compliance with applicable laws, rules and regulations governing market participants, which strictly prohibit intentional or abusive “naked shorting” of publicly traded securities.

Annex A

Information Statement

January 10, 2023

Dear Sorrento Therapeutics, Inc. Stockholder:

As Sorrento Therapeutics, Inc. (“Sorrento”) previously announced, on December 29, 2022 our board of directors declared a stock dividend (the “Dividend”) consisting of an aggregate of 76,000,000 shares (the “Dividend Stock”) of common stock, par value $0.0001 per share, of Scilex Holding Company (“Scilex Common Stock”) held by Sorrento to record holders of (i) Sorrento’s common stock, par value $0.0001 per share (such stock, the “Sorrento Common Stock” and such record holders, the “Record Common Holders”) as of the close of business on January 9, 2023 (the “Record Date”), and (ii) certain warrants to purchase Sorrento Common Stock that, among other things, have not been exercised prior to the ex-dividend date under the rules of The Nasdaq Stock Market LLC (and which have or may have the right to participate in the Dividend pursuant to the terms of their respective warrants) (the “Record Warrant Holders” and together with the Record Common Holders, the “Record Holders”), which Dividend shall be paid on January 19, 2023 (the “Payment Date”) and shall be apportioned on a pro rata basis among the Record Holders in accordance with each Record Holder’s ownership percentage of Sorrento Common Stock (assuming the full exercise of all outstanding warrants to purchase Sorrento Common Stock) as of the Record Date as set forth in the records of Sorrento’s transfer agent (with respect to the Record Common Holders) and Sorrento (with respect to the Record Warrant Holders) as of such date.

Scilex Holding Company (“Scilex”) is Sorrento’s majority-controlled, public-reporting subsidiary and the Scilex Common Stock is currently listed and traded on the Nasdaq Capital Market under the ticker symbol “SCLX”. As a public-reporting company, Scilex files periodic reports and other information with the SEC, which reports and other information can be found on the Securities and Exchange Commission’s Internet site at http://www.sec.gov.

Each Record Common Holder will receive (and each applicable Record Warrantholder will be entitled to receive following the exercise of such holder’s applicable warrants) 0.1410127 of a share of Scilex Common Stock for each one (1) share of Sorrento Common Stock held (or underlying the applicable warrants) by such Record Holder as of the close of business on the Record Date. The Dividend Stock will be subject to certain transfer restrictions through May 11, 2023, as more fully described in the attached information statement and notice. Payment of the Dividend is conditioned upon Sorrento’s board of directors not revoking the dividend prior to the Payment Date.

The Dividend Stock will be paid out in uncertificated (i.e., book-entry) form, which means that no physical share certificates will be delivered to you. No fractional shares of Scilex Common Stock will be issued in the Dividend. To the extent a Record Holder of Sorrento would otherwise be entitled to receive fractional shares of Scilex Common Stock in the Dividend, such holders shall receive cash (without interest or deduction) in lieu of such fractional shares in an amount equal to the product obtained by multiplying (a) the closing price of Scilex Common Stock on the Nasdaq Capital Market on the Record Date, by (b) the fraction of one share of Scilex Common Stock that such equityholder would have otherwise been entitled to receive as a Dividend in respect of shares of Sorrento Common Stock held by such Record Holder (after aggregating all such fractional shares otherwise issuable to such equityholder in connection with the Dividend).

You should consult your own tax advisor as to the particular tax consequences of the Dividend, including potential tax consequences under state, local, and non-U.S. tax laws.

The Dividend does not require Sorrento stockholder approval, and you do not need to take any action to receive your Dividend Stock. Upon the payment of the Dividend, you will own common stock in both Sorrento (if you retained this stock following the Record Date) and Scilex. Sorrento Common Stock is expected to continue to trade on the Nasdaq Capital Market under the ticker symbol “SRNE” and Scilex Common Stock is expected to continue to trade on the Nasdaq Capital Market under the ticker symbol “SCLX”.

Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex believes that its innovative non-opioid product portfolio has the potential to provide effective pain management therapies that can have a transformative impact on patients’ lives. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes.

We want to thank you for your support of Sorrento (including our subsidiary, Scilex) and it is my great privilege to welcome you as a future stockholder of Scilex, and we look forward to your continued support in the future.

The enclosed information statement and notice, which we are mailing to all Sorrento stockholders as of the close of business on the Record Date, describes the Dividend and refers you to important business and financial information about SCLX, including Scilex’s strategy and plans for near and long-term growth to generate value for its stockholders. We urge you to read this information statement and notice carefully.

Sincerely,

Henry Ji, Ph.D.

Chairman of the Board of Directors, Chief Executive Officer, and President of Sorrento Therapeutics, Inc. and the Executive Chairperson of Scilex Holding Company

INFORMATION STATEMENT
AND
NOTICE PURSUANT TO SECTION 151(F) AND SECTION 202
OF THE DELAWARE GENERAL CORPORATION LAW

SCILEX HOLDING COMPANY
Common Stock, par value $0.0001 per share

Unless the context otherwise requires, references in this information statement to “we,” “us,” “our,” “Scilex,” and “the Company” generally refer to Scilex Holding Company, together with its subsidiaries.

This information statement and notice pursuant to Section 151(f) and Section 202 of the General Corporation Law of the State of Delaware (“DGCL”), including the Summary of the Dividend attached hereto, is being furnished to you as a holder of common stock of Sorrento Therapeutics, Inc. (“Sorrento”). As Sorrento previously announced, on December 29, 2022 Sorrento’s board of directors (the “Sorrento Board”) declared a stock dividend (the “Dividend”) consisting of an aggregate of 76,000,000 shares (the “Dividend Stock”) of common stock, par value $0.0001 per share, of Scilex Holding Company (“Scilex Common Stock”) held by Sorrento to record holders of (i) Sorrento’s common stock, par value $0.0001 per share (such stock, the “Sorrento Common Stock” and such record holders, the “Record Common Holders”) as of the close of business on January 9, 2023 (the “Record Date”), and (ii) certain warrants to purchase Sorrento Common Stock that, among other things, have not been exercised prior to the ex-dividend date under the rules of The Nasdaq Stock Market LLC (and which have or may have the right to participate in the Dividend pursuant to the terms of their respective warrants) (the “Record Warrant Holders” and together with the Record Common Holders, the “Record Holders”), which Dividend (unless otherwise determined by the Board) shall be paid on January 19, 2023 (the “Payment Date”) and shall be apportioned on a pro rata basis among the Record Holders in accordance with each Record Holder’s ownership percentage of Sorrento Common Stock (assuming the full exercise of all outstanding warrants to purchase Sorrento Common Stock) as of the Record Date as set forth in the records of Sorrento’s transfer agent (with respect to the Record Common Holders) and Sorrento (with respect to the Record Warrant Holders) as of such date.

We are a majority-controlled, public-reporting subsidiary of Sorrento (which currently holds 96.7% of our currently outstanding voting stock). The Scilex Common Stock is currently listed and traded on the Nasdaq Capital Market under the ticker symbol “SCLX”. As a public-reporting company, Scilex files periodic reports and other information with the Securities and Exchange Commission (“SEC”), which reports and other information can be found on the Securities and Exchange Commission’s Internet site at http://www.sec.gov.

Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex believes that its innovative non-opioid product portfolio has the potential to provide effective pain management therapies that can have a transformative impact on patients’ lives. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Scilex launched its first commercial product in October 2018 and is developing its late-stage pipeline, which includes a pivotal Phase 3 candidate, a Phase 2 candidate and a Phase 1 candidate that is expected to enter into Phase 2 studies in the first half of 2023. Scilex’s commercial product, ZTlido (lidocaine topical system) 1.8% (“ZTlido”) is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration, for the relief of neuropathic pain associated with postherpetic neuralgia which is a form of post-shingles nerve pain. ZTlido possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period.

On the payment date for the Dividend, each Record Common Holder will receive (and each applicable Record Warrantholder will be entitled to receive following the exercise of such holder’s applicable warrants) 0.1410127 of a share of Scilex Common Stock for each one (1) share of Sorrento Common Stock held (or underlying the applicable warrants) by such Record Holder as of the close of business on the Record Date. In lieu of receiving fractional shares of Dividend Stock otherwise apportioned to the Record Common Holder, each Record Common Holder will receive cash representing the fair market value of such fractional shares. The Dividend Stock will be subject to certain transfer restrictions through May 11, 2023, as more fully described below. Payment of the Dividend is conditioned upon the Sorrento Board not revoking the dividend prior to the Payment Date.

Immediately after Sorrento completes the Dividend, Sorrento will hold approximately 52.1% of our currently outstanding voting stock.

You are urged to consult your tax advisor as to the particular U.S. federal, state, local, and non-U.S. tax consequences to you of receiving the Dividend.

If you are a corporate U.S. Holder (as defined below), you may be eligible for a dividends-received deduction (subject to certain requirements and limitations) with respect to your receipt of the Dividend, but the Dividend may be subject to certain “extraordinary dividend” provisions of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). Such provisions may result in a reduction in the adjusted basis of your Sorrento Common Stock and, potentially, recognition of gain.

If you are a non-corporate U.S. Holder (as defined below), the Dividend (including cash paid in lieu of fractional shares) to be made to you may be subject to backup withholding at a rate of 24% of the fair market value of such Dividend, unless you provide a correct taxpayer identification number by delivering a properly executed IRS Form W-9 (or successor form).

If you are not a U.S. Holder (as defined below), the Dividend (including cash paid in lieu of fractional shares) to be made to you may be subject to withholding at a rate of 30% of the fair market value of such Dividend, unless you establish an entitlement to a reduced rate of withholding by providing a properly executed IRS Form W-8 BEN, W-8BEN-E, or other applicable IRS Form W-8 (or successor form).

As used above, a “U.S. Holder” is a beneficial owner of Sorrento Common Stock that for U.S. federal income tax purposes is (a) an individual who is a citizen or resident of the United States; (b) a corporation created or organized under the laws of the United States, any state thereof or the District of Columbia; (c) an estate, the income of which is subject to United States federal income taxation regardless of its source; or (d) a trust, if a court within the United States is able to exercise primary supervision over the administration of the trust and one or more United States persons has the authority to control all substantial decisions of the trust, or, if the trust was in existence on August 20, 1996, and it has elected to continue to be treated as a United States person.

The Dividend (including cash paid in lieu of fractional shares of Dividend Stock) may be includable in ordinary taxable income to you in the year that includes the Payment Date to the extent of a portion of Sorrento’s current and accumulated earnings and profits. To the extent that the fair market value of the Dividend exceeds Sorrento’s current and accumulated earnings and profits, the Dividend will first be treated as a non-taxable return of basis, and any amounts in excess of such adjusted basis will constitute capital gain.

No vote or other action is required by you to receive the Dividend Stock. You will not be required to pay anything to Sorrento or Scilex for the new shares or to surrender any of your shares of Sorrento Common Stock. We are not asking you for a proxy, and you should not send us a proxy or your share certificates.

In reviewing this information statement, you should carefully review the reports and other information that we file with the SEC and we specifically refer you to our (i) registration statement on Form S-4 (File No. 333-264941), including the appendices and exhibits thereto, under the Securities Act, initially filed with the Securities and Exchange Commission (“SEC”) on May 13, 2022 (as subsequently amended), which was declared effective by the SEC on October 28, 2022 (the “Registration Statement”), (ii) final prospectus with respect to the Registration Statement, filed with the SEC on October 28, 2022 (the “Prospectus”), and (iii) Current Report on Form 8-K, filed with the SEC on November 17, 2022 (the “Super 8-K” and together with the Registration Statement and the Prospectus, the “Disclosure Materials”).

You should also carefully review the risks and uncertainties described under the heading “Risk Factors” in the Registration Statement and Prospectus.

Neither the Securities and Exchange Commission, nor any state securities commission has approved or disapproved these securities or determined if this information statement is truthful or complete. Any representation to the contrary is a criminal offense.

This information statement does not constitute an offer to sell or the solicitation of an offer to buy any securities.

The date of this information statement and notice pursuant to Section 151(f) and Section 202 of the DGCL is January 10, 2022.

SUMMARY OF THE DIVIDEND

Distributing Company:

Sorrento Therapeutics, Inc.

Distributed Company:

Scilex Holding Company, a majority-controlled, public reporting subsidiary of Sorrento

Dividend Stock:

Sorrento will distribute an aggregate of 76,000,000 shares of Scilex Common Stock in the Dividend.

Dividend Ratio:

Each Record Common Holder will receive (and each applicable Record Warrantholder will be entitled to receive following the exercise of such holder’s applicable warrants) 0.1410127 of a share of Scilex Common Stock for each one (1) share of Sorrento Common Stock held (or underlying the applicable warrants) by such Record Holder as of the close of business on the Record Date.

Treatment of Fractional Shares:

No fractional shares shall be issued in connection with the Dividend and the Record Holders who otherwise would be entitled to receive fractional shares of the Scilex Common Stock shall receive cash (without interest or deduction) in lieu of such fractional shares in an amount equal to the product obtained by multiplying (a) the closing price of Scilex Common Stock on the Nasdaq Capital Market on the Record Date, by (b) the fraction of one share of Scilex Common Stock that such Record Holder would have otherwise been entitled to receive as a Dividend in respect of shares of Sorrento Common Stock held by such Record Holder (after aggregating all such fractional shares otherwise issuable to such Record Holder in connection with the Dividend).

Record Date:

January 9, 2023

Payment Date:

January 19, 2023

Dividend:

On the Payment Date, Sorrento, with the assistance of Continental Stock Transfer & Trust Company, Scilex’s transfer agent (“Continental”), will electronically distribute shares of Scilex Common Stock to you via a registered position held at Continental until the expiration of the lock-up period described below. You will not be required to make any payment to Sorrento or Scilex or surrender or exchange your shares of Sorrento Common Stock to receive your shares of Scilex Common Stock on the Payment Date.

Market for Scilex Common Stock:

Our common stock is listed on the Nasdaq Capital Market under the symbol “SCLX”.

Transfer Agent for Scilex:

Continental Stock Transfer & Trust Company

Notice of Transfer Restrictions:

Notice is hereby given pursuant to Sections 151(f) and 202 of the Delaware General Corporation Law (“DGCL”), that the shares of Scilex Common Stock you will receive as a Dividend will be issued to you in uncertificated (i.e., book-entry) form.

The Dividend Stock you will receive on the Payment Date will be subject to restrictions on transfer until May 11, 2023 and your shares of Dividend Stock will reflect the following restrictive legend:

THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE TRANSFERRED, PLEDGED, HYPOTHECATED, LOANED, ENCUMBERED OR OTHERWISE DISPOSED OF WITHOUT THE CONSENT OF SCILEX HOLDING COMPANY (THE “COMPANY”) PRIOR TO MAY 11, 2023. A TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE SHALL BE DEEMED TO INCLUDE, WITHOUT LIMITATION, THE (A)  SALE OR ASSIGNMENT OF, OFFER TO SELL, CONTRACT OR AGREEMENT TO SELL, GRANT OF ANY OPTION TO PURCHASE OR OTHERWISE DISPOSE OF OR AGREEMENT TO DISPOSE OF, DIRECTLY OR INDIRECTLY, OR ESTABLISHMENT OR INCREASE OF A PUT EQUIVALENT POSITION OR LIQUIDATION WITH RESPECT TO OR DECREASE OF A CALL EQUIVALENT POSITION WITHIN THE MEANING OF SECTION 16 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (THE “EXCHANGE ACT”), WITH RESPECT TO, ANY SECURITY OF THE COMPANY, (B)  ENTRY INTO ANY SWAP OR OTHER ARRANGEMENT THAT TRANSFERS TO ANOTHER, IN WHOLE OR IN PART, ANY OF THE ECONOMIC CONSEQUENCES OF OWNERSHIP OF ANY SECURITY OF THE COMPANY, WHETHER ANY SUCH TRANSACTION IS TO BE SETTLED BY DELIVERY OF SUCH SECURITIES, IN CASH OR OTHERWISE, AND (C) ENGAGEMENT, WHETHER DIRECTLY OR INDIRECTLY, IN ANY (I) “SHORT SALE” (AS SUCH TERM IS DEFINED IN RULE 200 OF REGULATION SHO OF THE EXCHANGE ACT) OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE OR (II) HEDGING TRANSACTION, WHICH ESTABLISHES A NET SHORT POSITION WITH RESPECT TO ANY SECURITIES OF THE COMPANY (INCLUDING THE COMMON STOCK OF THE COMPANY), WITH RESPECT TO EACH OF CLAUSES (I) AND (II) HEREOF, EITHER FOR THE HOLDER’S OWN PRINCIPAL ACCOUNT OR FOR THE PRINCIPAL ACCOUNT OF ANY OTHER PERSON.

In addition, please be advised that the Company will furnish without charge to each stockholder of the Company who so requests the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock, or series thereof, of the Company and the qualifications, limitations or restrictions of such preferences and/or rights, which are fixed by the Restated Certificate of Incorporation of the Company, as amended from time to time. Any such request should be directed to the Secretary of the Company.



U.S. Federal Income Tax Consequences:

The Dividend (including cash paid in lieu of fractional shares of Dividend Stock) may be includable in ordinary taxable income to you in the year that includes the Payment Date to the extent of a portion of Sorrento’s current and accumulated earnings and profits. To the extent that the fair market value of the Dividend exceeds Sorrento’s current and accumulated earnings and profits, the Dividend will first be treated as a non-taxable return of basis, and any amounts in excess of such adjusted basis will constitute capital gain.

If you are a corporate U.S. Holder, you may be eligible for a dividends-received deduction (subject to certain requirements and limitations) with respect to your receipt of the Dividend, but the Dividend may be subject to certain “extraordinary dividend” provisions of the Code. Such provisions may result in a reduction of the adjusted basis of your Sorrento Common Stock and, potentially, recognition of gain.

If you are not a U.S. Holder, the Dividend to be made to you may be subject to withholding at a rate of 30% of the fair market value of such Dividend, unless you establish an entitlement to a reduced rate of withholding by providing a properly executed IRS Form W-8 BEN, W-8BEN-E, or other applicable IRS Form W-8 (or successor form).

This discussion does not address all aspects of U.S. federal income taxes. Furthermore, the discussion above is based upon the provisions of the Code, and Treasury regulations, rulings, and judicial decisions thereunder as of the date hereof, and such authorities may be repealed, revoked, or modified, possibly retroactively, and are subject to differing interpretations which could result in U.S. federal income tax consequences different from those discussed above. You are urged to consult your tax advisor as to the particular U.S. federal, state, local, and non-U.S. tax consequences to you of receiving the Dividend.

Corporate Information:

We were incorporated under the name “Vickers Vantage Corp. I” on February 21, 2020 as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. On November 9, 2022, we changed our jurisdiction of incorporation by deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware. On November 9, 2022, we changed our name to “Scilex Holding Company”.

Our principal executive offices are located at 960 San Antonio Road, Palo Alto, California 94303, and our telephone number is (650) 516-4310. Our website address is www.scilexholding.com. Any information contained on, or that can be accessed through, our website is not incorporated by reference into, nor is it in any way part of this information statement and notice and should not be relied upon in connection with making any decision with respect to an investment in our securities. We are required to file annual, quarterly and current reports, proxy statements and other information with the SEC. You may obtain any of the documents filed by us with the SEC at no cost from the SEC’s website at http://www.sec.gov.

Risk Factors:

Owning shares of Scilex Common Stock involves a high degree of risk. You should carefully read the risk factors, as well as the other information set forth in the Disclosure Materials (as defined below), including matters addressed in the section titled “Cautionary Note Regarding Forward-Looking Statements” (set forth in the Disclosure Materials).



WHERE YOU CAN FIND MORE INFORMATION

In connection with the completion of our previously announced business combination with Vickers Vantage Corp. I on November 10, 2022 (the “Business Combination”), we have filed (i) a registration statement on Form S-4 (File No. 333-264941), including exhibits, under the Securities Act, initially filed with the SEC on May 13, 2022 (as subsequently amended) and which was declared effective by the SEC on October 28, 2022 (the “Registration Statement”), (ii) a final prospectus with respect to the Registration Statement, filed with the SEC on October 28, 2022 (the “Prospectus”), and (iii) a Current Report on Form 8-K, filed with the SEC on November 17, 2022 (the “Super 8-K” and together with the Registration Statement and the Prospectus, the “Disclosure Materials”).

The Disclosure Materials contain detailed information regarding, among other things, our business, management, executive and director compensation, financial condition (including pro forma information related to the Business Combination, historical financial statements and our management’s discussion and analysis of our financial condition and results of operations), a description of our securities and certain relationships and related party transactions.

If you would like to request a copy of any of the Disclosure Materials, you may do so by contacting Angela Lamb at our transfer agent (Pacific Stock Transfer Company) by email at cs@pacificstocktransfer.com or by phone at 702-361-3033 and such materials will be provided to you free of charge.

In addition, because we are a reporting company we also file periodic reports and other information with the SEC. The SEC maintains an Internet site that contains such reports and other information regarding issuers that file electronically with the SEC, including Scilex Holding Company. The SEC’s Internet site can be found at http://www.sec.gov. You can read copies of such documents, along with copies of reports, proxy statements and other information filed by us with the SEC at the SEC’s website at http://www.sec.gov.

We also maintain a website at www.scilexholding.com. Through our website, we make available, free of charge, annual, quarterly and current reports, proxy statements and other information as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained on, or that may be accessed through, our website is not part of, and is not incorporated into, this information statement and notice and the inclusion of our website address in this information statement and notice is an inactive textual reference only.

 

 

 

 

Annex B

Broker List

Broker Name

Broker Address

 

Broker Name

Broker Address

ABN AMRO CLEARING CHICAGO LLC

175 WEST JACKSON BLVD.
CHICAGO
IL ILLINOIS
60604 US

 

Albert Fried & Company LLC

45 BROADWAY, 24TH FLOOR
24TH FLOOR
NEW YORK
NY NEW YORK
10006 US

AMALGAMATED BANK

275 7TH AVENUE
NEW YORK
NY NEW YORK
10003 US

 

AMERICAN ENTERPRISE INVESTMENT SERVICES INC.

682 AMERIPRISE FINANCIAL CENTER
MINNEAPOLIS
MN MINNESOTA
55474 US

APEX CLEARING CORPORATION

2 GATEWAY CENTER 283-299 MARKET ST
16TH FLOOR
NEWARK
NJ NEW JERSEY
07102-5005 US

 

BANK OF AMERICA, NA/GWIM TRUST OPERATIONS

901 MAIN STREET
12TH FLOOR
DALLAS
TX TEXAS
23113 US

BANK OF NEW YORK MELLON

111 SANDERS CREEK PARKWAY 2ND FLOOR
2ND FLOOR
EAST SYRACUSE
NY NEW YORK
13057 US.

 

BARCLAYS CAPITAL INC.

DTC CUSTODY PARTICIPANT- NY WINDOW -570 WASHINGTON BLVD (ATTN: ROSA HICKS-MILLER OR ROBERT MENDEZ
JERSEY CITY
NJ NEW JERSEY
07310 US

BARCLAYS CAPITAL INC.

DTC CUSTODY PARTICIPANT- NY WINDOW -570 WASHINGTON BLVD (ATTN: ROSA HICKS-MILLER OR ROBERT MENDEZ
JERSEY CITY
NJ NEW JERSEY
07310 US

 

BMO CAPITAL MARKETS CORP.

3 2ND STREET
12TH FLOOR
JERSEY CITY
NJ NEW JERSEY
07302 US

BMO HARRIS BANK NA/TRUST

11270 W PARK PL
MILWAUKEE
WI WISCONSIN
53224 US

 

BMO Nesbitt Burns Inc., Toronto

250 YONGE STREET, 7TH FLOOR
7TH FLOOR
TORONTO
ON ONTARIO
M5B 2M8 CA CANADA

BNP PARIBAS, NEW YORK BRANCH/BNP PARIBAS PRIME BROKERAGE CUSTODIAN

100 WEST 33RD STREET
3RD FLOOR
NEW YORK
NY NEW YORK
10001

 

BNP PARIBAS, NEW YORK BRANCH/BNP PARIBAS PRIME BROKERAGE CUSTODIAN

100 WEST 33RD STREET
3RD FLOOR
NEW YORK
NY NEW YORK
10001

BNY MELLON

PO BOX 392002
500 ROSS STREET
PITTSBURGH
PA PENNSYLVANIA
15262 US

 

BNY MELLON/WEALTH MANAGEMENT

1 FREEDOM VALLEY DRIVE
OAKS
PA PENNSYLVANIA
19456 US

BNYMELLON

111 SANDERS CREEK PARKWAY 2ND FLOOR
2ND FLOOR
EAST SYRACUSE
NY NEW YORK
13057 US

 

BNYMELLON/RE BARCLAYS CAPITAL SECURITIES LTD.

ONE WALL STREET
NEW YORK
NY NEW YORK
10286

BNYMELLON/RE CACEIS BANK LUXEMBOURG

500 Grant St.
BNY Mellon Center
PITTSBURGH
PA PENNSYLVANIA
15258

 

BNYMELLON/RE CACEIS BANK, NETHERLANDS

111 SANDERS CREEK PARKWAY
EAST SYRACUSE
NY NEW YORK
13057

BNYMELLON/RE CHARLES STANLEY AND COMPANY, LIMITED

111 SANDERS CREEK PARKWAY 2ND FLOOR
2ND FLOOR
EAST SYRACUSE
NY NEW YORK
13057 US

 

BNYMELLON/RE ETF - ISHARES DTC/NSCC

111 SANDERS CREEK PARKWAY
EAST SYRACUSE
NY NEW YORK
13057

BNYMELLON/RE WINTERFLOOD SECURITIES LTD

500 Grant St.
BNY Mellon Center
PITTSBURGH
PA PENNSYLVANIA
15258

 

BOFA

4804 Deer Lake Drive East
FL9-803-04-04- 4th floor
JACKSONVILLE
FL FLORIDA
32246 US

BOFA

4804 Deer Lake Drive East
FL9-803-04-04- 4th floor
JACKSONVILLE
FL FLORIDA
32246 US

 

BOFA SECURITIES INC

4804 Deer Lake Drive East
FL9-803-04-04- 4th floor
JACKSONVILLE
FL FLORIDA
32246 US

BROWN BROTHERS HARRIMAN & CO.

140 BROADWAY
ATTN: CORPORATE ACTIONS VAULT
NEW YORK
NY NEW YORK
10005 US

 

BROWN BROTHERS HARRIMAN & CO./ETF

140 BROADWAY
NEW YORK
NY NEW YORK
10005

CALDWELL SECURITIES LTD./CDS**

55 UNIVERSITY AVENUE
SUITE 340
TORONTO
ON ONTARIO
M5J 2H7 CANADA

 

CANACCORD GENUITY CORP.

609 GRANVILLE ST
VANCOUVER
BC BRITISH COLUMBIA
V7Y 1H2 CA CANADA

CANTOR, FITZGERALD & CO.

135 E 57TH ST 5TH FL
NEW YORK
NY NEW YORK
10041 US

 

CDS CLEARING AND DEPOSITORY SERVICES INC.

100 ADELAIDE STREET WEST
TORONTO
ON ONTARIO
M5H 1S3 CA CANADA

CETERA INVESTMENT SERVICES LLC

400 FIRST STREET SOUTH, SUITE 300
SUITE 300
ST. CLOUD
MN MINNESOTA
56302-0283 US

 

CHARLES SCHWAB & CO., INC.

211 MAIN STREET
SAN FRANCISCO
CA CALIFORNIA
94105 US

CI INVESTMENT SERVICES INC.

199 BAY STREET
SUITE 2600
TORONTO
ON ONTARIO
M5L 1E2 CA CANADA

 

CIBC WORLD MARKETS INC./CDS**

161 BAY STREET 10 FL
TORONTO
ON ONTARIO
M5J 2S8 CA CANADA

CITIBANK, N.A./ETF

3800 CITIGROUP CENTER
B2/2
TAMPA
FL FLORIDA
33610

 

CITIBANK, NATIONAL ASSOCIATION

3800 CITIBANK CENTER TAMPA
BLDG.B FIRST FLOOR ZONE 8
TAMPA
FL FLORIDA
33610-9122 US

CITIGROUP GLOBAL MARKETS, INC.

580 CROSSPOINT PARKWAY
GETZVILLE
NY NEW YORK
14068 US

 

CLEAR STREET LLC

4 World Trade Center, 45th Floor
150 Greenwich Street
NEW YORK
NY NEW YORK
10007

CLEARSTREET IO

55 BROADWAY (SUITE 2102)
CORPORATE ACTIONS
NEW YORK
NEW YORK
10006 US

 

COMMERCE BANK

922 WALNUT STREET
MAIL STOP TBTS-2
KANSAS CITY
MO MISSOURI
64106 US

COR CLEARING LLC

9300 UNDERWOOD AVE
SUITE 400
OMAHA
NE NEBRASKA
68114 US

 

Credential Securities Inc.

800-1111 WEST GEORGIA STREET
VANCOUVER
BC BRITISH COLUMBIA
V6E 4T6 CA CANADA

CREST INTERNATIONAL NOMINEES LIMITED

33 CANNON STREET
LONDON
EC4M 5SB GB UNITED KINGDO

 

CURVATURE SECURITIES, LLC

39 MAIN STREET
CHATHAM
NJ NEW JERSEY
07928 US

D.A. DAVIDSON & CO.

8 3RD STREET NORTH
GREAT FALLS
MT MONTANA
59401 US

 

DEPOSITO CENTRAL DE VALORES S.A., DEPOSITO DE VALORES

AVENIDA APOQUINDO # 4001
FLOOR 12, C.P.
7550162, SANTIAGO
CL CHILE

DESJARDINS SECURITIES INC.

1253 McGill College
10TH FLOOR
MONTREAL
QUEBEC
H3B 2Y5 CA CANADA

 

DEUTSCHE BANK AG NY/US CUSTODY

1251 Avenue Of The Americas
NEW YORK
NY NEW YORK
10020

DEUTSCHE BANK SECURITIES INC.

60 WALL STREET
9TH FLOOR
NEW YORK
NY NEW YORK
10005 US

 

DRIVEWEALTH, LLC

15 EXCHANGE PLACE
10TH FLOOR
JERSEY CITY
NEW JERSEY
07302

E*TRADE CLEARING LLC

HARBORSIDE FINANCIAL CENTER
501 PLAZA 11
JERSEY CITY
NJ NEW JERSEY
07311 US

 

EDWARD D. JONES & CO., L.P.

12555 MANCHESTER ROAD
ST. LOUIS
MO MISSOURI
63131-3729 US

EDWARD D. JONES & CO., L.P.

201 PROGRESS PARKWAY
MARYLAND HEIGHTS
MO MISSOURI
63043 US

 

FIDELITY CLEARING CANADA ULC/CDS**

483 BAY ST.
SOUTH TOWER
TORONTO
ON ONTARIO
M5G2N7 CA CANADA

FIFTH THIRD BANK

5001 KINGSLEY DRIVE
MAIL DROP 1MOB28
CINCINNATI
OH OHIO
45227 US

 

FOLIO INVESTMENTS, INC.

8180 GREENSBORO DRIVE
8TH FLOOR
MCLEAN
VA VIRGINIA
22102 US

FUTU CLEARING INC.

12750 Merit Drive
SUITE 475
DALLAS
TX TEXAS
75251

 

GMP SECURITIES L.P.

145 KING STREET WEST, SUITE 300
11TH FLOOR
TORONTO
ON ONTARIO
MJ5 1J8 CA CANADA

GOLDMAN, SACHS & CO. LLC

222 SOUTH MAIN STREET
Attn: Mandatory Corporate Actions
SALT LAKE CITY
UT UTAH
84101 US

 

HAYWOOD SECURITIES INC./CDS**

200 BURRARD ST
WATERFRONT CENTRE SUITE 700
VANCOUVER
BC BRITISH COLUMBIA
V6C 3L6 CANADA

HILLTOP SECURITIES INC.

1201 ELM ST.
35TH FLOOR
DALLAS
TX TEXAS
75270 US

 

HRT FINANCIAL LLC

150 GREENWICH STREET (ATTN: SETTLEMENT) FOUR WORLD TRADE CENTER
57TH FLOOR
NEW YORK
NY NEW YORK
10007 US

HSBC BANK USA, NA/HSBC CUSTODY & CLEARING SERVICES FOR STOCK LOAN

452 FIFTH AVENUE
ATTN: HBUS CCS SETTS
NEW YORK
NY NEW YORK
10018 US

 

HSBC BANK USA, NATIONAL ASSOCIATION

452 FIFTH AVENUE
ATTN: HBUS CCS SETTS
NEW YORK
NEW YORK
10018 US

INTERACTIVE BROKERS LLC

2 PICKWICK PLAZA
2ND FLOOR
GREENWICH
CT CONNECTICUT
06830 US

 

J.P. MORGAN CHASE BANK NA/FBO BLACKROCK CTF

1111 POLARIS PARKWAY
COLUMBUS
OH OHIO
43240

J.P. MORGAN CLEARING CORP.

FOUR CHASE METROTECH CENTER
3RD FLOOR
BROOKLYN
NY NEW YORK
11201 US

 

JANNEY MONTGOMERY SCOTT LLC

1717 ARCH STREET
17TH FLOOR
PHILADELPHIA
PA PENNSYLVANIA
19103 US

JEFFERIES LLC

101 HUDSON STREET, 11th Floor
NEW JERSEY
NJ NEW JERSEY
07302 US

 

JPMORGAN CHASE BANK, NATIONAL ASSOCIATION

FOUR CHASE METROTECH CENTER
3RD FLOOR
BROOKLYN
NY NEW YORK
11201 US

JPMORGAN CHASE BANK/EUROCLEAR BANK

FOUR CHASE METROTECH CENTER
3RD FLOOR
BROOKLYN
NY NEW YORK
11245 US

 

JPMORGAN CHASE BANK/IA

FOUR CHASE METROTECH CENTER
3RD FLOOR
BROOKLYN
NY NEW YORK
11201 US

KEYBANK NATIONAL ASSOCIATION

4900 TIEDEMAN RD
BROOKLYN
OH OHIO
44144 US

 

LAURENTIAN BANK SECURITIES INC.

1981 MCGILL COLLEGE AVE.
SUITE 100
MONTREAL
QUEBEC
H3A 3K3 CA CANADA

LPL FINANCIAL LLC

4707 EXECUTIVE DRIVE
SAN DIEGO
CA CALIFORNIA
92121 US

 

MANUFACTURERS AND TRADERS TRUST COMPANY

ONE M&T PLAZA
TRUST OPS 8TH FLOOR
BUFFALO
NY NEW YORK
14203 US

MANULIFE SECURITIES INCORPORATED

1235 NORTH SERVICE ROAD WEST
OAKVILLE
ON ONTARIO
L6M 2W2 CA CANADA

 

MARSCO INVESTMENT CORPORATION

101 EISENHOWER PARKWAY
ROSELAND
NJ NEW JERSEY
07068 US

MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED

4804 Deer Lake Drive East
FL9-803-04-04- 4th floor
JACKSONVILLE
FL FLORIDA
32246 US

 

MIRAE ASSET SECURITIES (USA) INC./STOCK LOAN CONDUIT ACCOUNT

810 SEVENTH AVE
37TH FLOOR
NEW YORK
NY NEW YORK
10019

MIRAE ASSET SECURITIES (USA), INC.

810 SEVENTH AVE
37TH FLOOR
NEW YORK
NY NEW YORK
10019

 

MITSUBISHI UFJ TRUST & BANKING CORPORATION, NEW YORK BRANCH

280 PARK AVE
39TH FL-WEST BLDG
NEW YORK
NY NEW YORK
10017

Morgan Stanley

1300 THAMES STREET
THAMES STREET WHARF
BALTIMORE
MD MARYLAND
21231 US

 

MORGAN STANLEY & CO. LLC

1300 THAMES ST.
BALTIMORE
MD MARYLAND

MORGAN STANLEY SMITH BARNEY LLC

1 NEW YORK PLAZA
39TH FLOOR
NEW YORK
NY NEW YORK
10004 US

 

MURIEL SIEBERT & CO., INC.

77 SUMMER STREET
3RD FLOOR
BOSTON
MA MASSACHUSETTS
02210 US

NATIONAL FINANCIAL SERVICES LLC

499 WASHINGTON BOULEVARD
5TH FLOOR
JERSEY CITY
NJ NEW JERSEY
07310 US

 

NBCN INC.

1010 rue De La Gauchetière
Mezzanine 100
MONTREAL
QUEBEC
H3B 5J2 CA CANADA

NOMURA INTERNATIONAL TRUST COMPANY

309 WEST 49TH STREET
10TH FLOOR
NEW YORK
NY NEW YORK
10019 US

 

ODLUM BROWN LIMITED

250 HOWE STREET
SUITE 1100
VANCOUVER
BC BRITISH COLUMBIA
V6C 3R8 CA CANADA

OPPENHEIMER & CO. INC.

85 BROAD STREET
NEW YORK
NY NEW YORK
10004 US

 

PERSHING LLC

1 PERSHING PLAZA
JERSEY CITY
NJ NEW JERSEY
07399 US

PHILLIP CAPITAL INC.

141 W. JACKSON BLVD. SUITE 3050
CHICAGO
IL ILLINOIS
60604 US

 

PI FINANCIAL CORP.

666 BURRARD ST
SUITE 1900
VANCOUVER
BC BRITISH COLUMBIA
V6C 3N1 CA CANADA

PNC BANK, NATIONAL ASSOCIATION

4100 W 150TH STREET
ASSET MOVEMENT TEAM 3RD FL, LOCATOR B7-YB17-03-03
CLEVELAND
OH OHIO
44135 US

 

PRINCIPAL BANK

711 HIGH STREET
DES MOINES
IA IOWA
50392

QUESTRADE INC./CDS**

5650 YONGE ST.,
Suite 1700
TORONTO
ON ONTARIO
M2M 4G3 CA CANADA

 

Raymond James & Associates, Inc.

880 CARILLON PKWY
ST. PETERSBURG
FL FLORIDA
33733-2749 US

RAYMOND JAMES LTD.

925 WEST GEORGIA STREET
SUITE 2200
VANCOUVER
BC BRITISH COLUMBIA
V6C 3L2 CA CANADA

 

RBC CAPITAL MARKETS, LLC

60 SOUTH 6TH ST.
MINNEAPOLIS
MN MINNESOTA
55402 US

RBC DOMINION SECURITIES INC

21 COMMERCE COURT SOUTH
2ND FLOOR
TORONTO
ON ONTARIO
M5L 1A7 CANADA

 

RELIANCE TRUST COMPANY

1100 ABERNATHY RD.
500 NORTHPARK SUITE 400
ATLANTA
GA GEORGIA
30113 US

RELIANCE TRUST COMPANY

4900 W. BROWN DEER RD
MILWAUKEE
WI WISCONSIN
53223 US

 

ROBERT W. BAIRD & CO. INCORPORATED

777 E WISCONSIN AVE
9TH FLOOR
MILWAUKEE
WI WISCONSIN
53202 US

ROBINHOOD SECURITIES, LLC

500 COLONIAL CENTER PARKWAY
SUITE 100
LAKE MARY
FL FLORIDA
32746 US

 

SAFRA SECURITIES LLC

546 5TH AVENUE
NEW YORK
NY NEW YORK
10036 US

SCOTIA CAPITAL (USA) INC.

150 KING STREET W
5TH FLOOR
TORONTO
ON ONTARIO
M5H 1J9 CA CANADA

 

SEI PRIVATE TRUST COMPANY

1 FREEDOM VALLEY DRIVE
OAKS
PA PENNSYLVANIA
19456 US

SEI PRIVATE TRUST COMPANY

1 FREEDOM VALLEY DRIVE
OAKS
PA PENNSYLVANIA
19456 US

 

SG AMERICAS SECURITIES, LLC

480 WASHINGTON BLVD.
20TH FLOOR
JERSEY CITY
NJ NEW JERSEY
07310 US

SSB - BLACKROCK INSTITUTIONAL TRUST

50 California Street
San Francisco
CA CALIFORNIA
94163

 

SSB - TRUST CUSTODY

30 ADELAIDE ST EAST
SUITE 800
TORONTO
ON ONTARIO
M5C 3G6 CA CANADA

SSB&T CO/CLIENT CUSTODY SERVICES

1776 HERITAGE DRIVE
NORTH QUINCY
MA MASSACHUSETTS
02171

 

STATE STREET BANK & TRUST CO

16 WALL STREET
5TH FLOOR
NEW YORK
NY NEW YORK
10005 US

STATE STREET BANK & TRUST COMPANY / ISHARES EUROPE

1776 HERITAGE DRIVE
NORTH QUINCY
MA MASSACHUSETTS
02171

 

STATE STREET BANK & TRUST/STATE STREET TOTALETF

1776 Heritage Drive
NORTH QUINCY
MA MASSACHUSETTS
02717

STATE STREET BANK AND TRUST COMPANY

30 ADELAIDE ST EAST
SUITE 800
TORONTO
ON ONTARIO
M5C 3G6 CA CANADA

 

STIFEL, NICOLAUS & COMPANY, INCORPORATED

501 N BROADWAY
ST. LOUIS
MO MISSOURI
63102 US

STONEX FINANCIAL INC.

2 PERIMETER PARK SOUTH
SUITE 100 W
BIRMINGHAM
AL ALABAMA
35243 US

 

TD AMERITRADE CLEARING, INC.

200 S 108TH AVE
OMAHA
NE NEBRASKA
68154 US

TD WATERHOUSE CANADA INC
ATTN: MANDATORY CORPORATE ACTIONS

77 BLOOR STREET WEST
3RD FLOOR
TORONTO
ON ONTARIO
M5S 1M2 CA CANADA

 

TEXAS TREASURY SAFEKEEPING TRUST COMPANY

208 E 10TH ST
AUSTIN
TX TEXAS
78701 US

THE BANK OF NEW YORK MELLON

500 GRANT STREET
27TH FLOOR
PITTSBURGH
PA PENNSYLVANIA
15258 US

 

THE HUNTINGTON NATIONAL BANK

7 EASTON OVAL EA4E62
COLUMBUS
OH OHIO
43209 US

THE NORTHERN TRUST COMPANY

333 South Wabash Ave, 32nd Floor
Attn: Trade Securities Processing
CHICAGO
IL ILLINOIS
60603 US

 

TRADESTATION SECURITIES, INC.

120 RIVERSIDE PLAZA
SUITE 1650
CHICAGO
IL ILLINOIS
60606 US

U.S. BANCORP INVESTMENTS, INC.

60 LIVINGSTON AVE
EP-MN-WN1B
ST. PAUL
MN MINNESOTA
55107-1419 US

 

U.S. BANK N.A./ETF

1555 N RIVER CENTER DRIVE
MILWAUKEE
WI WISCONSIN
53212

U.S. BANK NATIONAL ASSOCIATION

1555 NORTH RIVERCENTER DRIVE, SUITE 302
SUITE 302
MILWAUKEE
WI WISCONSIN
53212 US

 

UBS AG

480 WASHINGTON BLVD.
12TH FLOOR
JERSEY CITY
NJ NEW JERSEY
07310 US

UBS FINANCIAL SERVICES INC.

1000 HARBOR BOULEVARD
WEEHAWKEN
NJ NEW JERSEY
07086 US

 

UBS SECURITIES LLC

677 WASHINGTON BLVD
STAMFORD
CT CONNECTICUT
06901 US

UMB BANK, NATIONAL ASSOCIATION

928 GRAND BLVD
KANSAS CITY
MO MISSOURI
64106 US

 

VANGUARD MARKETING CORPORATION

100 VANGUARD BLVD
MALVERN
PA PENNSYLVANIA
19355 US

VELOCITY CLEARING, LLC

1301 Route 36
Suite 109 (Attn: Chris Felicetti)
HAZLET
NEW JERSEY
7730 US

 

VELOX CLEARING LLC

2400 E. KATELLA AVENUE
SUITE 725A
ANAHEIM
CA CALIFORNIA
92806 US

VIRTU AMERICAS LLC

ONE LIBERTY PLAZA, 165 BROADWAY
5TH FLOOR
NEW YORK
NY NEW YORK
10006 US

 

VISION FINANCIAL MARKETS LLC

4 HIGH RIDGE PARK
SUITE 100
STAMFORD
CT CONNECTICUT
06905 US

WEDBUSH SECURITIES INC

1000 WILSHIRE BLVD
8TH FLOOR
LOS ANGELES
CA CALIFORNIA
90017 US

 

WEDBUSH SECURITIES INC.

1000 WILSHIRE BLVD.
LOS ANGELES
CA CALIFORNIA
90017 US

WELLS FARGO BANK, N.A./SIG

733 MARQUETTE AVE 4TH FLOOR
MAC N9306-04D
MINNEAPOLIS
MN MINNESOTA
55402 US

 

WELLS FARGO CLEARING SERVICES LLC

1 NORTH JEFFERSON
MAIL CODE: H0006-094
ST. LOUIS
MO MISSOURI
63103 US

WELLS FARGO SECURITIES, LLC

1525 WEST W T HARRIS BLVD
CHARLOTTE
NC NORTH CAROLINA
28262 US

 

WILSON-DAVIS & CO., INC.

236 SOUTH MAIN STREET
SALT LAKE CITY
UT UTAH
84101 US

About Scilex Holding Company 

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life. Results from the Phase III Pivotal Trial C.L.E.A.R Program for SEMDEXATM, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with moderate to severe pain.  Scilex launched its first commercial product in October 2018, in-licensed a commercial product in June 2022, and is developing its late-stage pipeline, which includes a pivotal Phase 3 candidate and one Phase 2 and one Phase 1 candidate.  Its commercial product, ZTlido® (lidocaine topical system) 1.8%, or ZTlido®, is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain.  Scilex in-licensed the exclusive right to commercialize Gloperba® (colchicine USP) oral solution, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. Scilex is planning to commercialize Gloperba® in 2023 and is well-positioned to market and distribute the product. Scilex’s three product candidates are SP-102 (injectable dexamethasone sodium phosphate viscous gel product containing 10 mg dexamethasone), or SEMDEXA™, a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, with FDA Fast Track status; SP-103 (lidocaine topical system) 5.4%, a Phase 2, triple-strength formulation of ZTlido®, for the treatment of low back pain, with FDA Fast Track status; and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule, for the treatment of chronic pain, fibromyalgia in multiple Phase 1 programs expected to be initiated this year. For further information regarding the SP-102 Phase 3 efficacy trial, see NCT identifier NCT03372161 – Corticosteroid Lumbar Epidural Analgesia for Radiculopathy – Full Text View – ClinicalTrials.gov.

Scilex Holding Company is headquartered in Palo Alto, California, with operations in both Palo Alto and San Diego, California. For further information please visit www.scilexholding.com.

About Sorrento Therapeutics, Inc.

Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as Abivertinib, next-generation tyrosine kinase inhibitors (“TKIs”), fully human antibodies (“G-MAB™ library”), immuno-cellular therapies (“DAR-T™”), antibody-drug conjugates (“ADCs”), and oncolytic virus (“Seprehvec™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including STI-1558, COVI-MSC™; and diagnostic test solutions, including COVIMARK™.

Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a TRPV1 agonist, non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of postherpetic neuralgia (PHN). RTX has been cleared for a Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients. Positive final results from the Phase III Pivotal Trial C.L.E.A.R. Program for SEMDEXA™, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. ZTlido® was approved by the FDA on February 28, 2018.

For more information visit www.sorrentotherapeutics.com.

Contacts:

For Scilex Holding Company

Jaisim Shah
Chief Executive Officer
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310

Email: jshah@scilexpharma.com

Website:  www.sorrentotherapeutics.com and www.scilexholding.com

Investors and Media Contact:
Elizabeth Czerepak
Email: mediarelations@sorrentotherapeutics.com
Website: www.sorrentotherapeutics.com

Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

G-MAB™, DAR-T™, Seprehvec™, SOFUSA™, COVI-MSC™, COVIMARK™, Ovydso™ and FujoveeTM are trademarks of Sorrento Therapeutics, Inc.

SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company.  A proprietary name review by the FDA is planned.

ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.

Gloperba® is an exclusive, transferable license to use the trademark by Scilex Holding Company.

All other trademarks are the property of their respective owners.

© 2023 Sorrento Therapeutics, Inc. All Rights Reserved.